Drug General Information (ID: DDI0S6XMW4)
Drug Name			Mefloquine		Drug Info		Dolasetron		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antimalarial Agents				Antiemetics
Structure

Mechanism of Mefloquine-Dolasetron Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Mefloquine				Dolasetron
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Mefloquine and Dolasetron

Recommended Action
Management		Caution is advised if dolasetron is used concomitantly with other agents that prolong the QT, PR and/or QRS interval, especially in the elderly and patients with known risk factors. An ECG should be obtained in these patients before initiating dolasetron and periodically during treatment. Patients should be advised to seek medical attention if they experience dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope. Dolasetron should be avoided in patients with complete heart block or at risk for complete heart block, unless they have an implanted pacemaker.

References
1	Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.